256 results about "Pet imaging" patented technology

The present application relates to a PET imaging method and apparatus based on optical flow registration, and a device and a storage medium. The method comprises: correcting the position of an MR image, and extracting a first feature map of the PET image and a second feature map of a corrected MR image; performing feature enhancement processing of a spatial dimension and a channel dimension on both the first feature map and the second feature map, and fusing feature enhancement processing results of the spatial dimension and the channel dimension to generate a first multi-modal enhanced feature map of the PET image and a second multi-modal enhanced feature map of the corrected MR image; and fusing the first multi-modal enhanced feature map and the second multi-modal enhanced feature map by means of a cross-modal feature fusion module and using a multi-head cross-attention mechanism, so as to generate a multi-modal fused feature map, and on the basis of the multi-modal fused feature map, generating a reconstructed PET image. By means of the present application, the features of PET and MR can be effectively fused to obtain a clearer reconstructed PET image.

A method and system for determining a PET image of the scan volume based on one or more PET sub-images is provided. The method may include determining a scan volume of a subject supported by a scan table; dividing the scan volume into one or more scan regions; for each scan region of the one or more scan regions, determining whether there is a physiological motion in the scan region; generating, based on a result of the determination, a PET sub-image of the scan region based on first PET data of the scan region acquired in a first mode or based, at least in part, on second PET data of the scan region acquired in a second mode; and generating a PET image of the scan volume based on one or more PET sub-images.

A system and a method for PET imaging may be provided. Scan data of an object collected by a PET scan over a scan time period may be obtained. A plurality of target sets of scan data may be determined from the scan data based on a preset condition. Each of the plurality of target sets of scan data may correspond to a target sub-time period in the scan time period. One or more intermediate images corresponding to one or more sub-time periods different from the plurality of target sub-time periods in the scan time period may be generated based on the plurality of target sets of scan data. A target image sequence of the object may be generated based on the plurality of target sets of scan data and the one or more intermediate images.

The present application provides a method for preparing a liquid composition containing Compound I, which comprises a step of purifying a crude product containing Compound I by high performance liquid chromatography, and its use in myocardial perfusion PET imaging, wherein the mobile phase used in the purification step by high performance liquid chromatography contains ethanol and water. By optimizing the process parameters and process flow, it can be applied to large-scale batch activity production and meet the needs of automation. The resulting myocardial perfusion PET contrast agent has high radiochemical purity, high activity concentration, good product stability, and high and stable yield or output.

The invention discloses a radioactive labeling method of [18F] trifluoromethyl terminal olefin in the technical field of organic synthesis, under the condition of room temperature, 3, 3-difluoroallyl sulfosalt is used as a precursor, [18F] KF / K222 or [18F] TBAF is used as a fluorinating reagent, acetonitrile is used as a solvent, very high radiochemical yield can be obtained within 30 seconds, the tolerance of functional groups is excellent, and the method is suitable for industrial production. The specific reaction formula is as follows: # imgabs0 #. The method provides a simple and efficient way for producing the [18F] trifluoromethylated terminal olefin compound, so that the [18F] trifluoromethylated terminal olefin compound can be applied to positron emission tomography imaging. According to the method for preparing the 3, 3-difluoroallyl sulfur salt compound, the raw materials are easy to obtain, the cost is low, the operation is simple and convenient, safety and controllability are realized, and the radiation yield of the obtained product is high.

The embodiment of the invention discloses a double-nuclide PET reconstruction method and device based on a joint Poisson model, and the method comprises the steps: coincidence data collection and random three-coincidence estimation: retaining the photon correlation in decay through a coincidence delay window, and estimating the random three-coincidence through the photon irrelevance between decay; establishing a combined Poisson distribution model, introducing impure electron nuclides, pure electron nuclides and random radioactive source distribution into the distribution model at the same time, and constructing a combined Poisson likelihood function; constructing a prior function according to the image features, and forming a target function with the combined Poisson likelihood function; and solving the maximum posteriori estimation of the target function to obtain the spatial distribution of non-pure electron nuclides, pure electron nuclides and random radioactive sources at the same time. The dual-nuclide PET imaging method can be directly applied to the dual-nuclide PET imaging field based on triple coincidence, and has the advantages of being capable of effectively inhibiting random triple coincidence artifacts and the like.

The present invention relates to labeled compounds suitable for positron emission tomography (PET) imaging and / or fluorescence imaging such as near-infrared fluorescence imaging (NIRF). The invention further relates to the use of these compounds for carrying out PET scans. imaging calcium sensing receptor (CSR)-positive organs. excising parathyroid tissue. protecting parathyroid tissue during thyroid surgery, and treating disorder(s) of a CSR-positive tissue in a subject.

The invention discloses a method, device and equipment for determining kinetic parameters based on PET imaging and a medium, and the method comprises the steps: determining a tracer agent output function according to a blood input function and two atrioventricular dynamic models; according to the dynamic PET image set and the tracer output function, performing iterative solution on the two-atrioventricular dynamic model to obtain model dynamic parameters of the two-atrioventricular dynamic model; determining a dynamic parameter image according to the model dynamic parameters; wherein the dynamic PET image set represents a PET image set within a preset duration after the tracer is injected, the preset duration is greater than or equal to 30 minutes and less than 60 minutes, the two atrioventricular dynamic models correspond to a blood atrioventricle and a tissue atrioventricle, and the blood input function represents activity values of the tracer in the blood atrioventricle at different scanning moments; and the tracer output function represents the sum result of the activity value of the tracer in the blood chamber and the activity value of the tracer in the tissue chamber, so that the inspection flux and the use efficiency of the PET imaging equipment are improved.

The invention discloses a PET image reconstruction method and device with a self-attenuation correction function, a medium and a product. The method comprises the steps that measurement data and the total tracer agent concentration corresponding to the measurement data are obtained, and the measurement data are obtained through a positron emission tomography imaging method based on flight time; on the basis of the measurement data, the total concentration, a pre-stored concentration map updating rule, a pre-stored attenuation sinogram updating rule and a pre-stored sensitivity matrix, the concentration map and the attenuation sinogram are alternately updated until iteration is finished, a target concentration map and a target attenuation sinogram are obtained, and the target concentration map serves as a target PET image; the concentration map update rule and the attenuation sinogram update rule are both determined based on a minimization model, the minimization model is used for minimizing a negative logarithm maximum likelihood function of a measurement data model, the minimization model comprises a concentration constraint term, and the measurement data model is used for constraining attenuation of measurement data in an exponential form. According to the embodiment of the invention, the PET image with high image quality can be reconstructed through self-attenuation correction.

The invention discloses an Alzheimer's disease plasma diagnosis marker based on plasma pTau217 and application of the Alzheimer's disease plasma diagnosis marker. The plasma biomarker provided by the invention is pTau217, pTau217 / A beta 1-40 or pTau217 / A beta 1-42, and the detection of the plasma biomarker not only belongs to a reliable, simple and convenient non-invasive means, but also can efficiently evaluate the disease risk of the Alzheimer's disease. The method can replace the traditional Alzheimer disease detection method, such as cerebrospinal fluid amyloid protein detection and PET imaging, and is easy to clinically and widely apply. The method has an important application value.

The invention provides a benzene azepine derivative, a radioactive probe and application thereof, and belongs to the technical field of biological medicine. According to the present invention, the benzazepine derivative is modified, and the hydrophilic or lipophilic side chain is introduced, such that the prepared benzazepine derivative can be used as the V2R targeting precursor for application, the specific V2R targeting can be achieved, and the new molecular tool is provided for the subsequent V2R positive tumor diagnosis and treatment. The radioactive probe combined with the 68Ga marker shows a good tumor imaging effect, can realize PET imaging of V2R positive tumors, is helpful for improving the accuracy of tumor diagnosis, can also be used for evaluating the treatment effect, has a relatively high target / non-target ratio, can better display the distribution of whole body V2R receptors, and has a good application prospect. The invention has various applications in cancer diagnosis and treatment.

The invention relates to a carbonic anhydrase IX targeted molecular probe and application thereof, and belongs to the technical field of nuclear medicine. The invention provides carbonic anhydrase IX targeted molecular probes 18F-SAZ and 18F-DAZ, and the two molecular probes have the following advantages: firstly, the specificity is strong, and the molecular probes can be selectively taken in a CAIX positive tumor part so as to better distinguish carbonic anhydrase IX negative and positive tumors; secondly, the compound can quickly reach a carbonic anhydrase IX positive tumor, a better imaging effect can be obtained within 30 minutes, and the compound has better retention property; and thirdly, the in-vivo metabolism is rapid, the biological half-life period is shorter, the in-vivo clearing time is obviously shorter than that of an antibody molecular probe, and the safety is higher. In conclusion, the two molecular probes can dynamically monitor the change of the level of carbonic anhydrase IX in tumor cells in real time through PET imaging, and have great application prospects in diagnosis of positive tumors of carbonic anhydrase IX.

The invention relates to the technical field of molecular probes, and particularly discloses a molecular probe of a targeted tyrosine kinase receptor as well as a preparation method and application of the molecular probe, the molecular probe comprises radioisotope, targeted polypeptide and a chelating group, the targeted polypeptide specifically targets the tyrosine kinase receptor, the chelating group is connected with the targeted polypeptide to form a targeted precursor, and the chelating group is connected with the targeted polypeptide to form the targeted precursor. The radioactive isotope labeled precursor forms a molecular probe, and the sequence of the targeted polypeptide is shown as any one of SEQ ID No.1-8. The targeting polypeptide has good targeting property on a tyrosine kinase receptor coded by an RET gene, can realize specific high uptake in a cell line of NEPC, has relatively good biological safety, can realize accurate imaging aiming at NEPC, and clearly and durably visualizes NEPC tumors in PET imaging; meanwhile, the molecular probe can effectively delay the growth capacity of NEPC, can provide a new treatment choice for NEPC patients, and has good clinical transformation potential.

A positron emission tomography, PET, imaging system (100) includes a plurality of detector modules (1301 . . . i). Each detector module (1301 . . . i) includes a cooling unit (130c1 . . . i) with a heat-transfer region (170). The heat transfer region (170) of each cooling unit (130c1 . . . i) is thermally coupled to a photodetector array (130b1 . . . i) of the corresponding detector module for cooling the photodetector array. The cooling units are configured to be fluidically coupled in parallel to at least one cooling fluid source.

Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. In the past, AD could only be definitively diagnosed by brain biopsy or upon autopsy after a patient died. These methods, which demonstrate the presence of the characteristic plaque and tangle lesions in the brain, are still considered the gold standard for the pathological diagnoses of AD. However, in the clinical setting brain biopsy is rarely performed and diagnosis depends on a battery of neurological, psychometric and biochemical tests, including the measurement of biochemical markers such as the ApoE and tau proteins or the beta-amyloid peptide in cerebrospinal fluid and blood. The present invention discloses and describes panels of makers that are differentially expressed in the disease state relative to their expression in the normal state and, in particular, identifies and describes panels of makers associated with neurocognitive disorders. Such biomarker panel might have considerable value in triaging patients with early memory disorders to yet more specific but more invasive and costly approaches such as molecular markers in CSF and on PET imaging in clinical trials and possibly in clinical practice.

The invention relates to a PD-L1 targeted biphenyl radioactive tracer and application thereof, and belongs to the technical field of PET imaging. The invention provides a series of PD-L1 targeted biphenyl radioactive tracers which comprise [18F] LG-2, [18F] LG-3, [18F] LG-13, [18F] LG-14, [18F] LG-15 and the like, the series of biphenyl radioactive tracers have good in-vitro stability, can be specifically combined with PD-L1, and are relatively good in targeting specificity, and therefore, the series of biphenyl radioactive tracers can be applied to the field of radioactive tracers. The series of biphenyl radioactive tracers can noninvasively, accurately, dynamically and systemically monitor the expression level and change of PD-L1 in tumors from the molecular level in real time through PET imaging, and then the curative effect of PD-1 / PD-L1 immunotherapy on tumor patients is effectively evaluated.

The invention discloses an early evaluation method, device and system for Alzheimer's disease. The method comprises the following steps: detecting whether a user completes a preset short-term task or not; when the user completes the preset short-term task, acquiring physiological data of the user; inputting the physiological data into an evaluation model to obtain a risk score, the evaluation model being an Alzheimer's disease early evaluation model; and generating an assessment report according to the risk score. According to the method, when the user completes the preset short-term task, the physiological data of the user are collected and input into the Alzheimer's disease early assessment model to obtain the risk score, so that the assessment report is obtained, the assessment report can be obtained without lumbar puncture, PET imaging detection and high-resolution MRI detection of the user, and the user experience is improved. The compliance is improved; the detection cost is reduced; and the detection timeliness is improved.

A method and a system for PET imaging may be provided. PET data of a subject collected by a PET scan of the subject and a physiological signal relating to a physiological motion of the subject during the PET scan may be obtained. Gated PET images corresponding to physiological phases of the subject may be generated based on the PET data and the physiological signal. Further, for each physiological phase, a first attenuation map of the subject corresponding to the physiological phase may be generated based on the gated PET image corresponding to the physiological phase, and an attenuation corrected gated PET image corresponding to the physiological phase may be generated based on the first attenuation map and a portion of the PET data corresponding to the physiological phase. A target PET image corresponding to a reference physiological phase may be generated based on the attenuation corrected gated PET images.

The invention discloses a human-derived hysteromyoma targeting peptide and application thereof, the sequence of the targeting peptide is selected from SEQ ID NO: 1 to SEQ ID NO: 5, and the SEQ ID NO: 1 (VN12) is the most preferable. The fusion protein is obtained by screening through a phage display technology, and has high hysteromyoma targeting specificity and low immunogenicity. The targeting peptide can be coupled with nuclide or fluorescent dye, and is used for accurate PET imaging, fluorescent diagnosis and intraoperative navigation of hysteromyoma. Experiments prove that the molecular marker is specifically enriched in tumor tissues (the tumor / muscle ratio is 60), the biological safety is good, the problems of insufficient diagnosis sensitivity and large treatment wound in the prior art are solved, and the molecular marker has a great application prospect in diagnosis and treatment of hysteromyoma.

The invention provides an FAPI trimer compound, a preparation method of the FAPI trimer compound, a PET developer based on the FAPI trimer compound and a preparation method of the developer. Amphipathic polyethylene glycol chains and trimeric structures in molecules of the FAPI trimer compound can improve in-vivo dynamic characteristics of the compound, and the in-vivo dynamic characteristics of the compound can be improved. The residence time in the tumor is prolonged; the PET imaging agent based on the FAPI trimer compound can improve the uptake and imaging effects of the PET imaging agent in tumors, and has good application prospects in PET imaging, preparation of drugs for diagnosing FAP-q expressed tumors and drugs for marking therapeutic nuclide (177Lu or 90Y) to treat the FAP-q expressed tumors in the future.

The invention discloses a PET (positron emission tomography) imaging agent, a precursor and a probe for targeting an EphA2 receptor as well as a preparation method and application of the PET imaging agent, the precursor and the probe, and a radioactive probe which is formed by labeling a chelating agent (such as DOTA and NOTA) and a radionuclide (such as 68Ga) by taking bicyclic peptide as a targeting group is specifically combined with the EphA2 receptor highly expressed on the surface of a tumor cell. According to the invention, a conformation limitation strategy is adopted for transforming the peptide probe targeting EphA2 for the first time, the bicyclic peptide radioactive probe with excellent targeting performance and in-vivo imaging effect is obtained, the tumor uptake value is high, and tumor and non-tumor imaging is clear; and successful imaging in a fibrosarcoma model. According to the EphA2 receptor-targeted PET imaging agent provided by the invention, the precursor, namely the probe, has the advantages of simplicity in preparation, good targeting property, excellent imaging effect and the like, can be used for PET imaging diagnosis, prognosis evaluation and targeted therapy guidance of EphA2 positive tumors, and has good clinical value.

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

The present application provides a preparation method for a liquid composition comprising Compound I and its use in myocardial perfusion PET imaging. The method comprising the following steps: purifying a crude product comprising the compound I by using high-performance liquid chromatography, wherein a mobile phase used in the high-performance liquid chromatography purification step comprises ethanol and water. By optimizing process parameters and technological process, the method of the present application can be applied to large-scale activity production and meet automation needs. An obtained myocardial perfusion PET imaging agent of this application has high radiochemical purity, high activity concentration, good product stability, and high and stable yield or productivity.

A method for estimating noise equivalent counts includes one or more times during a scan of an object with a positron emission tomography (PET) scanner, wherein a plurality of coincidence events are detected by a detector array of the PET scanner, performing the following actions. The actions include obtaining a total of the plurality of coincidence events, estimating random coincidence events, and estimating scatter coincidence events. The actions include estimating true coincidence events based on the total of the plurality of coincidence events, the estimated random coincidence events, and the estimated scatter coincidence events. The actions include determining a scatter fraction based on the estimated scatter events and true coincidence events. The actions include estimating the noise equivalent counts based at least on the scatter fraction, the total of the plurality of coincidence events, the estimated true coincidence events, the estimated scatter coincidence events, and the estimated random coincidence events.

The present invention provides a method for preparing and using a Trop2-specific integrated diagnostic and therapeutic molecular imaging probe. The Trop2-specific molecular imaging probe, constructed based on the Trop2-specific nanoantibodies WWD98 and WWD328, can be used for immuno-PET imaging. Immuno-PET imaging using the probe can non-invasively display Trop2 expression within tumors, achieving non-invasive visualization of human Trop2 molecular expression. This provides a better method for diagnosing and monitoring Trop2-positive solid tumors and can further enable non-invasive diagnosis of various tumors, such as pancreatic cancer and gastric cancer. The probe of the present invention has the advantages of a simple preparation process, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and ease of clinical translation.

The present invention provides a radiolabeled compound targeting cannabinoid receptor type 2 labeled with the radionuclide 18F. The present invention also provides a process for the preparation of said compound and its use as a positron emission tomography (PET) imaging agent.

The invention discloses a polypeptide PET (Polyethylene Terephthalate) developer targeting FGFR1 (Fibroblast Growth Factor Receptor). The structure of the polypeptide PET developer targeting FGFR1 is shown as a formula (1), r1 is a bifunctional chelating group and is selected from at least one of a formula (2) or a formula (3); Mn < + > is marked radionuclide chelated with R1; the radionuclide Mn < + > is selected from at least one of [Al18F] < 2 + >, < 68 > Ga < 3 + >, < 64 > Cu < 2 + > and < 177 > Lu < 3 + >. The structure of the FGFR1-targeted polypeptide PET imaging agent comprises polypeptide, a bifunctional chelating agent and radionuclide, the preparation method is simple and rapid, the yield is high, the PET imaging agent is good in stability, high in water solubility and high in in-vivo blood removal speed, the PET imaging agent is mainly metabolized by the kidney and can be specifically taken by a high-expression tumor site of the FGFR1, and the PET imaging agent can be widely applied to biological function imaging.

The invention discloses a method for preparing < 18 > F-m-fluorobenzylguanidine, and solves the technical problems of complex reaction steps, low radiochemical yield and low specific activity in a method for synthesizing < 18 > F-mFBG. The invention comprises a phenolic ether precursor compound of a core skeleton corresponding to 18F-mFBG, a synthesis method of the phenolic ether precursor compound, and a method for realizing F-18 labeling and preparation of mFBG by using the precursor compound. Specifically, 18F-mFBG labeling and preparation are realized by constructing a key phenolic ether precursor compound and performing simple and efficient photocatalytic deoxidation fluorination reaction on aromatic hydrocarbon. The method has the advantages of few steps, high yield, simplicity and convenience in operation, good repeatability and good automatic production potential. The radioactive tracer 18F-mFBG synthesized by the method is high in specific activity, chemical purity and radioactive purity, and has important value for clinical popularization of targeted NET molecular function PET imaging.

The application belongs to the technical field of biological medicine, and discloses a synthesis method of aryl F-18 labeled sulfuryl chloride and application of the aryl F-18 labeled sulfuryl chloride in amine compound labeling. The method takes thiophenol derivative as a labeling precursor, obtains F-18 labeled thiophenol intermediate through photocatalytic aryl F-18 fluorination reaction, and then obtains aryl F-18 labeled sulfuryl chloride through N-chlorosuccinimide oxidation chlorination. The obtained aryl F-18 labeled sulfuryl chloride (4-[ 18 F] fluorobenzenesulfonyl chloride) can occur sulfurylization reaction with various amine compounds at room temperature, and the radiochemical conversion rate is as high as 98%. The application is successfully applied to novel synthesis of AMPA receptor PET imaging agent[ 18 F]2 (the conversion rate is 96%, which is much higher than 13% reported in the literature). The application has the advantages of mild reaction condition, high conversion rate and wide substrate application range, and provides an efficient method for innovative preparation of F-18 labeled PET probes.

A compound or pharmaceutically acceptable salt thereof has at least one bis-phosphonate or bisphosphonate ester group, and a positron emitting radionuclide Po. The positron emitting radionuclide Po is attached to the at least one bisphosphonate or bisphosphonate ester group. The compound may be useful in a method of diagnosis of amyloidosis, such as cardiac amyloidosis.